Daily non-political popular news in brief.

USC and second sight announce European clinical trial for Argus II retinal implant

Artificial retinal implant takes next step by expanding clinical trial.

Read more »

Keywords: usc, sight, announce, european, clinical, trial, argus, retinal, implant, argu

« Previous | Next »

Similar news on "USC and second sight announce European clinical trial for Argus II retinal implant":

1. New chemotherapy regimen prolongs survival in difficult-to-treat childhood brainstem gliomas
   09-25-2007 · EurekAlert!
   Spanish researchers told the European Cancer Conference in Barcelona that they have found that a chemotherapy regimen of irinotecan and cisplatin produced rapid clinical responses in childhood brain stem glioma, and shrank the tumors by more than 20 percent in all six children enrolled in a clinical trial.
   Similar news · Read more »
   
2. Rutgers biomaterial debuts in clinical trials of new stent
   10-18-2007 · EurekAlert!
   A revolutionary, new biomaterial, developed at the New Jersey Center for Biomaterials at Rutgers University, has moved from the lab bench to field testing in record time. This achievement, a product of a breakthrough methodology in biomaterials discovery, is the enabling technology behind a coronary stent undergoing its first-in-human clinical trial in Germany and in Brazil.
   Similar news · Read more »
   
3. Half of patients with active early rheumatoid arthritis achieved clinical remission
   11-07-2007 · EurekAlert!
   Amgen and Wyeth Pharmaceuticals, a division of Wyeth, today announced that data from a multicenter, randomized, double-blind trial of ENBREL plus methotrexate showed that 50 percent of patients with active early rheumatoid arthritis achieved clinical remission at one year.
   Similar news · Read more »
   
4. Experimental MS drug shows promise, offers new window on disease
   02-13-2008 · EurekAlert!
   A drug therapy currently used to treat non-Hodgkin's lymphoma and rheumatoid arthritis had a significant effect in treating the most common form of multiple sclerosis in a small, short-term clinical trial led by scientists at University of California-San Francisco.
   Similar news · Read more »
   
5. European space loses leading figure
   10-16-2006 · European Space Agency (ESA)
   ESA PR 37-2006. It is with great regret that we announce the death of Michel Bignier, which occurred on 12 October.
   Similar news · Read more »
   
6. Promising Antiobesity Drug Fails To Produce Clinically Meaningful Weight Loss
   10-05-2006 · ScienceDaily
   A drug designed to target a powerful hunger-stimulating factor that has long been considered a prime target for antiobesity therapy failed to produce clinically meaningful weight loss in obese people in a long-term clinical trial. People taking the drug known as MK-0557 for a year consistently lost about three pounds more than those taking a placebo, researchers reported in the October issue of the journal Cell Metabolism, published by Cell Press.
   Similar news · Read more »
   
7. New data show ACTOS(r) (pioglitazone HCl) halted progression of atherosclerosis as indicated by CIMT
   11-13-2006 · EurekAlert!
   Researchers today presented data showing that ACTOS® (pioglitazone HCl) halted the progression of atherosclerosis as measured by carotid intima-media thickness (CIMT) in patients with type 2 diabetes. Results from the clinical trial, CHICAGO (Carotid intima-media tHICkness in Atherosclerosis using pioGlitazOne), are part of a late-breaker presentation at the American Heart Association's Scientific Sessions 2006, coincidentally being held in Chicago, and coincide with an early online issue of the Journal of the American Medical Association.
   Similar news · Read more »
   
8. Study finds lapatinib shows promise as therapy for inflammatory breast cancer
   12-14-2006 · EurekAlert!
   In the first multi-center clinical trial conducted to better understand the complexities of a rare, aggressive and often lethal form of breast cancer, researchers have discovered that the experimental biological agent, lapatinib, successfully and specifically treats inflammatory breast cancer (IBC).
   Similar news · Read more »
   
9. NIAID DNA vaccine for H5N1 avian influenza enters human trial
   01-03-2007 · EurekAlert!
   The first human trial of a DNA vaccine designed to prevent H5N1 avian influenza infection began on December 21, 2006, when the vaccine was administered to the first volunteer at the National Institutes of Health (NIH) Clinical Center in Bethesda, MD. Scientists from the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), one of the NIH Institutes, designed the vaccine. The vaccine does not contain any infectious material from the influenza virus.
   Similar news · Read more »
   
10. Conflicting attitudes hinder participation in clinical trials
    02-01-2007 · EurekAlert!
    Women have conflicting attitudes about participating in clinical trials because of uncertainties about trusting the experimenters, fear of the trial itself and hope that the research will result in medical progress, according to a new study at Wake Forest University School of Medicine.
    Similar news · Read more »